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Question #1: 
What does “methicillin-sensitive” mean? 
It means that the isolate is susceptible to 
beta-lactam antibiotics with anti-
staphylococcal activity such as oxacillin, 
nafcillin, cefazolin and others. In contrast, 
methicillin-resistant Staphylococcus aureus 
(MRSA) is resistant to most beta-lactams 
due to a modification of the penicillin-
binding proteins that results in lower avidity. 
Methicillin is actually not commercially 
available in the United States but when 
resistance was described in 1961, methicillin 
was used to treat S. aureus infections. So the 
terminology remains in use because of its 
historic role.  
 
Question #2: 
Does MSSA bacteremia have better 
outcomes than MRSA bacteremia? 
Yes. Decreased efficacy of vancomycin 
against Staphylococcus aureus (vancomycin 
is the first line antibiotic for MRSA 
bacteremia) and delay in appropriate 
treatment were postulated to be the reasons 
behind this difference.
1, 2
 But they are both 
very serious infections, associated with 
longer hospital stays and high mortality 
rates.  
 
Question #3: 
What are the first line antibiotic choices 
for MSSA bacteremia? 
Nafcillin (or oxacillin) and cefazolin. 
Cefazolin is not inferior to nafcillin in terms 
of outcomes and it is associated to decreased 
rates of adverse events compared to 
nafcillin.
3, 4
 Additionally, cefazolin is less 
expensive than nafcillin.  
 
Question #4: 
In what clinical scenarios should I choose 
nafcillin or cefazolin over the other? 
Cefazolin needs dose adjustment based on 
renal function, which we use as an 
advantage in patients with end-stage renal 
disease on hemodialysis. We usually 
recommend 2 grams after each dialysis 
session, with addition of an extra gram 
before the long interdialytic period. As a 
bonus, there is no need to place a long-term 
line.  
Patients with history of non-
anaphylactic allergy to penicillin may 
tolerate cefazolin very well.  
In patients with central nervous 
system infection, nafcillin is the choice 
because cefazolin has inadequate blood-
brain barrier penetrability.  
 
Question #5: 
Should I always consult Infectious 
Diseases (ID) in cases of MSSA 
bacteremia? 
Yes. If available at your institution, an ID 
consult has been associated with better 
adherence to quality measures, decreased 
rates of treatment failure, decreased 
mortality and decreased readmission rates.
5-7
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Question #6: 
Can I use levofloxacin for MSSA 
bacteremia, if antibiogram shows 
susceptibility? 
No. Staphylococcus aureus will rapidly 
develop resistant and treatment will fail.  
 
Question #7: 
Should I treat MSSA bacteremia for 2, 4 
or 6 weeks? 
With either MSSA or MRSA bacteremia, a 
two-week duration of therapy should only be 
used in cases of Staphylococcus aureus 
bacteremia in which all of the following 
criteria are met:
8, 9
 
- No bone or joint infection 
- Endocarditis excluded with 
echocardiography 
- Defervescence within 72 hours with 
negative follow-up blood cultures  
- No prosthetic material (pacer, valve, 
arthroplasty) 
- No evidence of metastatic infection 
- No diabetes or immunosuppression  
Otherwise, Staphylococcus aureus 
bacteremia requires 4-6 weeks of therapy 
(endocarditis and bone infections will 
require at least 6 weeks). 
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